Karyn A Goodman1, Fang-Shu Ou2, Nathan C Hall3, Tanios Bekaii-Saab4, Briant Fruth2, Erin Twohy2, Michael O Meyers5, Daniel J Boffa6, Kisha Mitchell7, Wendy L Frankel8, Donna Niedzwiecki9, Anne Noonan8, Yelena Y Janjigian10, Paul J Thurmes11, Alan P Venook12, Jeffrey A Meyerhardt13, Eileen M O'Reilly10, David H Ilson10. 1. Icahn School of Medicine at Mount Sinai, New York, NY. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN. 3. Hospital of the University of Pennsylvania, Philadelphia, PA. 4. Mayo Clinic Cancer Center, Scottsdale, AZ. 5. University of North Carolina at Chapel Hill, Chapel Hill, NC. 6. Yale University, New Haven, CT. 7. Greenwich Hospital, Greenwich, CT. 8. The Ohio State University Wexner Medical Center, Columbus, OH. 9. Duke University, Durham, NC. 10. Memorial Sloan Kettering Cancer Center, New York, NY. 11. Metro Minnesota Community Oncology Research Consortium, Minneapolis, MN. 12. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. 13. Dana Farber/Partners CancerCare, Boston, MA.
Abstract
PURPOSE: To evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma. METHODS: After baseline PET, patients were randomly assigned to an induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP). Repeat PET was performed after induction; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders (< 35% decrease in SUV) crossed over to the alternative chemotherapy during chemoradiation (50.4 Gy/28 fractions). PET responders (≥ 35% decrease in SUV) continued on the same chemotherapy during chemoradiation. Patients underwent surgery at 6 weeks postchemoradiation. Primary end point was pathologic complete response (pCR) rate in nonresponders after switching chemotherapy. RESULTS: Two hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET. The pCR rates for PET nonresponders after induction FOLFOX who crossed over to CP (n = 39) or after induction CP who changed to FOLFOX (n = 50) was 18.0% (95% CI, 7.5 to 33.5) and 20% (95% CI, 10 to 33.7), respectively. The pCR rate in responders who received induction FOLFOX was 40.3% (95% CI, 28.9 to 52.5) and 14.1% (95% CI, 6.6 to 25.0) in responders to CP. With a median follow-up of 5.2 years, median overall survival was 48.8 months (95% CI, 33.2 months to not estimable) for PET responders and 27.4 months (95% CI, 19.4 months to not estimable) for nonresponders. For induction FOLFOX patients who were PET responders, median survival was not reached. CONCLUSION: Early response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.
PURPOSE: To evaluate the use of early assessment of chemotherapy responsiveness by positron emission tomography (PET) imaging to tailor therapy in patients with esophageal and esophagogastric junction adenocarcinoma. METHODS: After baseline PET, patients were randomly assigned to an induction chemotherapy regimen: modified oxaliplatin, leucovorin, and fluorouracil (FOLFOX) or carboplatin-paclitaxel (CP). Repeat PET was performed after induction; change in maximum standardized uptake value (SUV) from baseline was assessed. PET nonresponders (< 35% decrease in SUV) crossed over to the alternative chemotherapy during chemoradiation (50.4 Gy/28 fractions). PET responders (≥ 35% decrease in SUV) continued on the same chemotherapy during chemoradiation. Patients underwent surgery at 6 weeks postchemoradiation. Primary end point was pathologic complete response (pCR) rate in nonresponders after switching chemotherapy. RESULTS: Two hundred forty-one eligible patients received Protocol treatment, of whom 225 had an evaluable repeat PET. The pCR rates for PET nonresponders after induction FOLFOX who crossed over to CP (n = 39) or after induction CP who changed to FOLFOX (n = 50) was 18.0% (95% CI, 7.5 to 33.5) and 20% (95% CI, 10 to 33.7), respectively. The pCR rate in responders who received induction FOLFOX was 40.3% (95% CI, 28.9 to 52.5) and 14.1% (95% CI, 6.6 to 25.0) in responders to CP. With a median follow-up of 5.2 years, median overall survival was 48.8 months (95% CI, 33.2 months to not estimable) for PET responders and 27.4 months (95% CI, 19.4 months to not estimable) for nonresponders. For induction FOLFOX patients who were PET responders, median survival was not reached. CONCLUSION: Early response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.
Authors: Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham Journal: Lancet Oncol Date: 2005-09 Impact factor: 41.316
Authors: Lawrence P Leichman; Bryan H Goldman; Pierre O Bohanes; Heinz J Lenz; Charles R Thomas; Kevin G Billingsley; Christopher L Corless; Syma Iqbal; Philip J Gold; Jacqueline K Benedetti; Kathleen D Danenberg; Charles D Blanke Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Somnath Mukherjee; Christopher Nicholas Hurt; Sarah Gwynne; David Sebag-Montefiore; Ganesh Radhakrishna; Simon Gollins; Maria Hawkins; Heike I Grabsch; Gareth Jones; Stephen Falk; Ricky Sharma; Andrew Bateman; Rajarshi Roy; Ruby Ray; Jo Canham; Gareth Griffiths; Tim Maughan; Tom Crosby Journal: Eur J Cancer Date: 2017-02-08 Impact factor: 9.162
Authors: Yusuke Shimodaira; Rebecca S Slack; Kazuto Harada; Hsiang-Chun Chen; Tara Sagebiel; Manoop S Bhutani; Jeffrey H Lee; Brian Weston; Elena Elimova; Quan Lin; Fatemeh G Amlashi; Dilsa Mizrak Kaya; Mariela A Blum; Jack A Roth; Stephen G Swisher; Heath D Skinner; Wayne L Hofstetter; Jane E Rogers; Jaennette Mares; Irene Thomas; Dipen M Maru; Ritsuko Komaki; Garrett Walsh; Jaffer A Ajani Journal: Br J Cancer Date: 2017-12-12 Impact factor: 7.640
Authors: William A Hall; Eric Paulson; X Allen Li; Beth Erickson; Christopher Schultz; Alison Tree; Musaddiq Awan; Daniel A Low; Brigid A McDonald; Travis Salzillo; Carri K Glide-Hurst; Amar U Kishan; Clifton D Fuller Journal: CA Cancer J Clin Date: 2021-11-18 Impact factor: 508.702
Authors: Florian Huemer; Stefan Hecht; Bernhard Scharinger; Verena Schlintl; Gabriel Rinnerthaler; Konstantin Schlick; Ronald Heregger; Thomas Melchardt; Angela Wimmer; Iris Mühlbacher; Oliver Owen Koch; Daniel Neureiter; Eckhard Klieser; Sara Seyedinia; Mohsen Beheshti; Richard Greil; Lukas Weiss Journal: J Cancer Res Clin Oncol Date: 2022-07-21 Impact factor: 4.322
Authors: Go Nishikawa; Pratyusha Banik; Rajat Thawani; Adel Kardosh; Stephanie G Wood; Nima Nabavizadeh; Emerson Y Chen Journal: J Gastrointest Oncol Date: 2022-06
Authors: Farshid Dayyani; Brian R Smith; Ninh T Nguyen; Shaun Daly; Marcelo W Hinojosa; Steven N Seyedin; Jeffrey Kuo; Jason B Samarasena; John G Lee; Thomas H Taylor; May T Cho; Maheswari Senthil Journal: Future Oncol Date: 2022-05-23 Impact factor: 3.674
Authors: David T Pointer; Jordan A McDonald; Samer A Naffouje; Rutika Mehta; Jason B Fleming; Jacques P Fontaine; Gregory Y Lauwers; Jessica M Frakes; Sarah E Hoffe; Jose M Pimiento Journal: J Surg Oncol Date: 2022-05-16 Impact factor: 2.885
Authors: Smita Sihag; Samuel C Nussenzweig; Henry S Walch; Meier Hsu; Kay See Tan; Sergio De La Torre; Yelena Y Janjigian; Steven B Maron; Geoffrey Y Ku; Laura H Tang; Pari M Shah; Abraham Wu; David R Jones; David B Solit; Nikolaus Schultz; Karuna Ganesh; Michael F Berger; Daniela Molena Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Caitlin A Harrington; Rebecca A Carr; Meier Hsu; Kay See Tan; Smita Sihag; Prasad S Adusumilli; Manjit S Bains; Matthew J Bott; James M Isbell; Bernard J Park; Gaetano Rocco; Valerie W Rusch; David R Jones; Daniela Molena Journal: J Thorac Cardiovasc Surg Date: 2022-03-01 Impact factor: 6.439
Authors: Rebecca A Carr; Meier Hsu; Caitlin A Harrington; Kay See Tan; Manjit S Bains; Matthew J Bott; David H Ilson; James M Isbell; Yelena Y Janjigian; Steven B Maron; Bernard J Park; Valerie W Rusch; Smita Sihag; Abraham J Wu; David R Jones; Geoffrey Y Ku; Daniela Molena Journal: Ann Surg Date: 2021-08-13 Impact factor: 13.787
Authors: Radka Obermannova; Iveta Selingerova; Zdenek Rehak; Vaclav Jedlicka; Marek Slavik; Pavel Fabian; Ivo Novotny; Milada Zemanova; Hana Studentova; Peter Grell; Lenka Zdrazilova Dubska; Regina Demlova; Tomas Harustiak; Renata Hejnova; Igor Kiss; Rostislav Vyzula Journal: Ther Adv Med Oncol Date: 2022-01-05 Impact factor: 8.168